Avalo Therapeutics
Avalo Therapeutics
AVTX
NASDAQ
7.39
USD
4.23%
About
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes).
AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 49.0K |
| Three Month Average Volume | 377.9K |
| High Low | |
| Fifty-Two Week High | 71.04 USD |
| Fifty-Two Week Low | 3.9501 USD |
| Fifty-Two Week High Date | 14 Sep 2023 |
| Fifty-Two Week Low Date | 17 Jan 2024 |
| Price and Volume | |
| Current Price | 7 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -38.65% |
| Thirteen Week Relative Price Change | -44.03% |
| Twenty-Six Week Relative Price Change | 44.03% |
| Fifty-Two Week Relative Price Change | -76.72% |
| Year-to-Date Relative Price Change | -35.04% |
| Price Change | |
| One Day Price Change | -22.65% |
| Thirteen Week Price Change | -40.09% |
| Twenty-Six Week Price Change | 58.37% |
| Five Day Price Change | -23.91% |
| Fifty-Two Week Price Change | -70.83% |
| Year-to-Date Price Change | -23.08% |
| Month-to-Date Price Change | -38.49% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 9.11007 USD |
| Book Value Per Share (Most Recent Quarter) | -2.08001 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -3.98877 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -12.23541 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -9.14371 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 6.92759 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.33465 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -113.5792 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -63.8218 USD |
| Normalized (Last Fiscal Year) | -104.4351 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -113.5792 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -60.1804 USD |
| Including Extraordinary Items (Last Fiscal Year) | -113.5792 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -63.8218 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 9.24852 USD |
| Cash Per Share (Most Recent Quarter) | 90.34261 USD |
| Cash Flow Per Share (Last Fiscal Year) | -113.009 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -14.95836 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -13.30585 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -486 |
| Cash Flow Revenue (Trailing Twelve Months) | -3,976 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -4,486.99% |
| Pretax Margin (Last Fiscal Year) | -1,638.77% |
| Pretax Margin (5 Year) | -620.45% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 33.26% |
| Gross Margin (Trailing Twelve Months) | 64.19% |
| Gross Margin (5 Year) | 84.69% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,421.57% |
| Operating Margin (Trailing Twelve Months) | -6,660.35% |
| Operating Margin (5 Year) | -607.66% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,639.50% |
| Net Profit Margin (Trailing Twelve Months) | -4,488.60% |
| Net Profit Margin (5 Year) | -613.58% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -63.84% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -22.83% |
| Revenue Change (Trailing Twelve Months) | -95.24% |
| Revenue Per Share Growth | -58.78% |
| Revenue Growth (5 Year) | -34.02% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -22.48% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 100.40% |
| EPS Change (Trailing Twelve Months) | 87.56% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -93,426,000 |
| Net Debt (Last Fiscal Year) | -7,415,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 9 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -30,838,000 |
| Free Cash Flow (Trailing Twelve Months) | -32,087,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -6 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -116.06% |
| Return on Assets (Trailing Twelve Months) | -54.66% |
| Return on Assets (5 Year) | -99.64% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -331.65% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -228.35% |
| Return on Investment (Trailing Twelve Months) | -529.15% |
| Return on Investment (5 Year) | -154.42% |